Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

Abstract Glioblastoma (GB) is the most frequent primary brain tumor in adults with a dismal prognosis despite aggressive treatment including surgical resection, radiotherapy and chemotherapy with the alkylating agent temozolomide. Thus far, the successful implementation of the concept of targeted th...

Full description

Bibliographic Details
Main Authors: Michael W. Ronellenfitsch, Pia S. Zeiner, Michel Mittelbronn, Hans Urban, Torsten Pietsch, Dirk Reuter, Christian Senft, Joachim P. Steinbach, Manfred Westphal, Patrick N. Harter
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Acta Neuropathologica Communications
Subjects:
Epidermal growth factor receptor
Mammalian target of rapamycin
Glioblastoma
Nimotuzumab
Biomarker
Targeted therapy
Online Access:http://link.springer.com/article/10.1186/s40478-018-0583-4

Internet

http://link.springer.com/article/10.1186/s40478-018-0583-4

Similar Items